AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Point72 Asset Management L.P.

Point72 Asset Management L.P. cut its stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 97.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,900 shares of the biotechnology company's stock after selling 846,200 shares during the period. Point72 Asset Management L.P. owned about 0.07% of AnaptysBio worth $449,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ANAB. Algert Global LLC boosted its position in AnaptysBio by 11.8% in the 2nd quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company's stock valued at $255,000 after buying an additional 1,078 shares during the period. Frazier Life Sciences Management L.P. boosted its holdings in shares of AnaptysBio by 140.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company's stock valued at $54,270,000 after purchasing an additional 1,265,891 shares during the period. Susquehanna Fundamental Investments LLC boosted its holdings in shares of AnaptysBio by 32.9% in the second quarter. Susquehanna Fundamental Investments LLC now owns 72,060 shares of the biotechnology company's stock valued at $1,806,000 after purchasing an additional 17,855 shares during the period. The Manufacturers Life Insurance Company grew its stake in AnaptysBio by 49.8% in the second quarter. The Manufacturers Life Insurance Company now owns 25,312 shares of the biotechnology company's stock worth $634,000 after purchasing an additional 8,418 shares in the last quarter. Finally, Alpha DNA Investment Management LLC purchased a new position in AnaptysBio during the 2nd quarter worth $399,000.

AnaptysBio Stock Down 3.0 %

Shares of AnaptysBio stock traded down $1.05 on Friday, reaching $33.98. The stock had a trading volume of 209,080 shares, compared to its average volume of 326,210. AnaptysBio, Inc. has a 1 year low of $13.36 and a 1 year high of $41.31. The company has a 50 day moving average price of $35.45 and a 200 day moving average price of $28.50. The stock has a market capitalization of $928.30 million, a P/E ratio of -5.53 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.82). The business had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. On average, analysts forecast that AnaptysBio, Inc. will post -6.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on ANAB. Truist Financial upped their target price on AnaptysBio from $20.00 to $30.00 and gave the stock a "hold" rating in a report on Thursday, August 15th. JPMorgan Chase & Co. upped their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 7th. HC Wainwright reissued a "buy" rating and set a $55.00 target price on shares of AnaptysBio in a research report on Wednesday, August 14th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $42.00 price target on shares of AnaptysBio in a research report on Thursday, September 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $51.10.

Insider Activity at AnaptysBio

In other AnaptysBio news, Director Hollings Renton sold 10,000 shares of the firm's stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $30.64, for a total value of $306,400.00. Following the completion of the sale, the director now owns 1,950 shares of the company's stock, valued at approximately $59,748. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Paul F. Lizzul sold 1,500 shares of the company's stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $35.00, for a total value of $52,500.00. Following the transaction, the insider now directly owns 11,618 shares of the company's stock, valued at $406,630. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Hollings Renton sold 10,000 shares of the firm's stock in a transaction on Monday, July 15th. The stock was sold at an average price of $30.64, for a total value of $306,400.00. Following the completion of the transaction, the director now owns 1,950 shares of the company's stock, valued at $59,748. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,940 shares of company stock valued at $1,251,836 in the last ninety days. Corporate insiders own 33.70% of the company's stock.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.